<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2021-4462</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-4462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние ожирения на эхокардиографические особенности и N-концевой предшественник мозгового натрийуретического пептида у больных с сердечной недостаточностью и промежуточной фракцией выброса левого желудочка: нерешенные вопросы</article-title><trans-title-group xml:lang="en"><trans-title>Impact of obesity on echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels in patients with heart failure with mid-range ejection fraction: unanswered questions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0613-829X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лясникова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyasnikova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лясникова Елена Анатольевна — кандидат медицинских наук, старший научный сотрудник НИО сердечной недостаточности.</p><p>Санкт-Петербург.</p><p>SPIN-код: 6143-6293</p></bio><bio xml:lang="en"><p>Elena A. Lyasnikova</p><p>St. Petersburg.</p></bio><email xlink:type="simple">elka77@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8869-8655</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куулар</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuular</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куулар Айлаана Александровна — аспирантка кафедры внутренних болезней Института Медицинского Образования.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">char_ai_al_91@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3372-6989</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павловская</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlovskaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павловская Алла Владимировна — клинический ординатор кафедры внутренних болезней Института Медицинского Образования.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">pavlovskaya.av@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власенко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasenko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Власенко Александр Николаевич — врач функциональной диагностики.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">alvlasenko131264@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1435-4286</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козленок</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlenok</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Козленок Андрей Валерьевич — кандидат медицинских наук, заведующий НИО физиологии кровообращения.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">avkozlenok@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0559-697X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабенко</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Babenko</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабенко Алина Юрьевна — доктор медицинских наук, заведующий НИЛ диабетологии Института эндокринологии.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">alina_babenko@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0139-5177</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситникова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitnikova</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ситникова Мария Юрьевна — доктор медицинских наук, заведующий НИО сердечной недостаточности.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">drsitnikova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2929-0980</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шляхто</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shlyakhto</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шляхто Евгений Владимирович — доктор медицинских наук, академик РАН, генеральный директор.</p><p>Санкт-Петербург.</p></bio><bio xml:lang="en"><p>St. Petersburg.</p></bio><email xlink:type="simple">e.shlyakhto@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НМИЦ им. В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>06</day><month>06</month><year>2021</year></pub-date><volume>26</volume><issue>6</issue><fpage>4462</fpage><lpage>4462</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лясникова Е.А., Куулар А.А., Павловская А.В., Власенко А.Н., Козленок А.В., Бабенко А.Ю., Ситникова М.Ю., Шляхто Е.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Лясникова Е.А., Куулар А.А., Павловская А.В., Власенко А.Н., Козленок А.В., Бабенко А.Ю., Ситникова М.Ю., Шляхто Е.В.</copyright-holder><copyright-holder xml:lang="en">Lyasnikova E.A., Kuular A.A., Pavlovskaya A.V., Vlasenko A.N., Kozlenok A.V., Babenko A.Y., Sitnikova M.Y., Shlyakhto E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/4462">https://russjcardiol.elpub.ru/jour/article/view/4462</self-uri><abstract><sec><title>Цель</title><p>Цель. Проанализировать и сопоставить клинико-эхокардиографические характеристики и сывороточные концентрации N-концевого предшественника мозгового натрийуретического пептида (NT-proBNP) в зависимости от основных факторов кардиометаболического риска, с акцентом на ожирение, у пациентов с сердечной недостаточностью (СН) и промежуточной фракцией выброса (СНпФВ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Включено 111 мужчин с постинфарктным кардиосклерозом и СНпФВ (средний возраст 60 лет) с клиническими проявлениями СН преимущественно II функционального класса. Эхокардиография (ЭхоКГ) и забор крови на NT-proBNP были проведены на фоне синусового ритма единовременно. Объём левого предсердия (ОЛП) и масса миокарда левого желудочка (ММЛЖ) индексировались к площади поверхности тела (ППТ) и степенной выраженности роста.</p></sec><sec><title>Результаты</title><p>Результаты. Сахарный диабет 2 типа, избыточный вес и ожирение диагностировались в 25%, 19%, 38% случаев, соответственно, и ассоциировались с более выраженными изменениями морфо-функциональных параметров левого желудочка. Межгрупповых различий среди пациентов с ожирением и без такового в индексных показателях ОЛП и ММЛЖ, приводимых к ППТ, выявлено не было, в то же время в группе с индексом массы тела (ИМТ) ≥30 кг/м2 значения ОЛП, приведенного к росту в квадрате, и ММЛЖ, приведенного к росту2,7, были больше (все р&lt;0,05). У 11% пациентов с ожирением изменений критериальных индексных параметров ОЛП или ММЛЖ, приведенных к ППТ, выявлено не было, однако значения, индексируемые к степенной выраженности роста, превышали нормативные показатели. У 20% пациентов с клиническими проявлениями стабильной СНпФВ и наличием структурно-функциональных ЭхоКГ критериев NT-proBNP был ≤125 пг/мл. Была выявлена обратная корреляция между NT-proBNP и ИМТ (r=-0,29; p=0,008), и меньшие значения маркера миокардиального стресса наблюдались в группе пациентов с ожирением (р=0,048).</p></sec><sec><title>Заключение</title><p>Заключение. Учитывая высокую встречаемость ожирения в когорте пациентов с СНпФВ и его способность занижать значение NT-proBNP, требуется модификация алгоритма для постановки диагноза СНпФВ: ориентация на клинические и персонализированные данные ЭхоКГ с учетом наличия ожирения и, возможно, индексация пороговых значений натрийуретических пептидов у пациентов, имеющих ИМТ ≥30 кг/м2. Вопросы индексации параметров ЭхоКГ в зависимости от показателей морфометрии у лиц с ожирением на сегодняшний день остаются открытыми, предопределяя ограничения в инструментальной диагностике СН на фоне фракции выброса левого желудочка &gt;40%, что требует поиска оптимальной стандартизации и выработки единого методологического подхода.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To analyze and compare the clinical, echocardiographic characteristics and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels depending on the central cardiometabolic risk factors, with a focus on obesity, in patients with heart failure (HF) with mid-range ejection fraction (HFmrEF).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 111 patients with old myocardial infarction and HFmrEF (men, 100%; mean age, 60 years) predominantly of NYHA class II. Echocardiography and blood sampling for NT-proBNP were performed with sinus rhythm. Left atrial volume (LAV) and left ventricular mass (LVM) were indexed to body surface area (BSA) and height raised to a power.</p></sec><sec><title>Results</title><p>Results. Type 2 diabetes, overweight and obesity were diagnosed in 25%, 19%, 38% of cases, respectively, and were associated with greater changes in the morphologic and functional left ventricular parameters. There were no intergroup differences among patients with and without obesity in the LAV and LVM indexed to BSA. However, in patients with a body mass index (BMI) ≥30 kg/m2, the LAV indexed to height squared and LVM indexed to height2,7 were higher (p&lt;0,05 for all). In 11% of obese patients, there were no changes in the criterion LAV or LVM values indexed to BSA, but the values indexed to height raised to a power exceeded the standard values. In 20% of patients with clinical manifestations of stable HFmrEF and structural and functional echocardiographic criteria, NT-proBNP were ≤125 pg/ml. An inverse correlation was found between NT-proBNP and BMI (r=-0,29; p=0,008), and lower values of myocardial stress marker were observed in obese patients (p=0,048).</p></sec><sec><title>Conclusion</title><p>Conclusion. Considering the high incidence of obesity in patients with HFmrEF and its ability to reduce NT-proBNP, an algorithm modification is required for diagnosing HFmrEF as follows: focus on clinical and personalized echocardiography data, taking into account the obesity and, possibly, indexing the threshold natriuretic peptide values in patients with BMI ≥30 kg/m2. The issues of indexation of echocardiographic parameters depending on morphometric parameters in obese patients today remain open, predetermining the limitations in diagnosis of heart failure with left ventricular ejection fraction &gt;40%. This requires the search for optimal standardization and the development of a unified methodological approach.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>СНпФВ</kwd><kwd>эхокардиография</kwd><kwd>NT-proBNP</kwd><kwd>диагностические шкалы сердечной недостаточности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>HFmrEF</kwd><kwd>echocardiography</kwd><kwd>NT-proBNP</kwd><kwd>heart failure diagnostic scales</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при поддержке гранта Министерства науки и высшего образования Российской Федерации (соглашение № 075-15-2020-800).</funding-statement><funding-statement xml:lang="en">The study was supported by a grant from the Ministry of Science and Higher Education of the Russian Federation (№ 075-152020-800).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Koh AS, Tay WT, Teng THK, et al. A comprehensive population based characterization of heart failure with mid-range ejection fraction: Characteristics and outcomes in HFmrEF. Eur J Heart Fail. 2017;19(12):1624-34. doi:10.1002/ejhf.945.</mixed-citation><mixed-citation xml:lang="en">Koh AS, Tay WT, Teng THK, et al. A comprehensive population based characterization of heart failure with mid-range ejection fraction: Characteristics and outcomes in HFmrEF. Eur J Heart Fail. 2017;19(12):1624-34. doi:10.1002/ejhf.945.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cleland JGF, Lyon AR, McDonagh T, McMurray JJV. The year in cardiology: heart failure Eur Heart J. 2020;41(12):1232-48. doi:10.1093/eurheartj/ehz949.</mixed-citation><mixed-citation xml:lang="en">Cleland JGF, Lyon AR, McDonagh T, McMurray JJV. The year in cardiology: heart failure Eur Heart J. 2020;41(12):1232-48. doi:10.1093/eurheartj/ehz949.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lund LH, Claggett B, Liu J, Lam CS, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum: Candesartan across the ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-9. doi:10.1002/ejhf.1149.</mixed-citation><mixed-citation xml:lang="en">Lund LH, Claggett B, Liu J, Lam CS, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum: Candesartan across the ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-9. doi:10.1002/ejhf.1149.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. doi:10.1002/ejhf.813.</mixed-citation><mixed-citation xml:lang="en">Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. doi:10.1002/ejhf.813.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951-8. doi:10.1093/eurheartj/ehx181.</mixed-citation><mixed-citation xml:lang="en">Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951-8. doi:10.1093/eurheartj/ehx181.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е. В., Недогода С.В., Конради А.О. и др. Концепция новых национальных клинических рекомендаций по ожирению. Российский кардиологический журнал. 2016;(4):7-13. doi:10.15829/1560-4071-2016-4-7-13.</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Nedogoda SV, Konradi AO, et al. The concept of novel national clinical guidelines on obesity. Russ J Cardiol. 2016;(4):7-13. (In Russ.) doi:10.15829/1560-4071-2016-4-7-13.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237-44. doi:10.1161/CIRCULATIONAHA.109.887893.</mixed-citation><mixed-citation xml:lang="en">Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237-44. doi:10.1161/CIRCULATIONAHA.109.887893.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e535-e578. doi:10.1161/CIR.0000000000000450.</mixed-citation><mixed-citation xml:lang="en">Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e535-e578. doi:10.1161/CIR.0000000000000450.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gentile F, Sciarrone P, Zamora E, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. Eur J Prev Cardiol. 2020;2047487320927610. doi:10.1177/2047487320927610.</mixed-citation><mixed-citation xml:lang="en">Gentile F, Sciarrone P, Zamora E, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. Eur J Prev Cardiol. 2020;2047487320927610. doi:10.1177/2047487320927610.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-9. doi:10.1016/j.ijcard.2018.04.001.</mixed-citation><mixed-citation xml:lang="en">Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-9. doi:10.1016/j.ijcard.2018.04.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Delepaul B, Robin G, Delmas C, et al. Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? ESC Heart Fail. 2017;4(2):99-104. doi:10.1002/ehf2.12131.</mixed-citation><mixed-citation xml:lang="en">Delepaul B, Robin G, Delmas C, et al. Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? ESC Heart Fail. 2017;4(2):99-104. doi:10.1002/ehf2.12131.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dadarlat-Pop A, Sitar-Taut A, Zdrenghea D, et al. Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure. Clin Interv Aging. 2020;15:547-56. doi:10.2147/CIA.S248158.</mixed-citation><mixed-citation xml:lang="en">Dadarlat-Pop A, Sitar-Taut A, Zdrenghea D, et al. Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure. Clin Interv Aging. 2020;15:547-56. doi:10.2147/CIA.S248158.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Singh M, Sethi A, Mishra AK, et al. Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size. J Am Heart Assoc. 2020;9(2):e014609. doi:10.1161/JAHA.119.014609.</mixed-citation><mixed-citation xml:lang="en">Singh M, Sethi A, Mishra AK, et al. Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size. J Am Heart Assoc. 2020;9(2):e014609. doi:10.1161/JAHA.119.014609.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28(7):727-54. doi:10.1016/j.echo.2015.05.002.</mixed-citation><mixed-citation xml:lang="en">Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28(7):727-54. doi:10.1016/j.echo.2015.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ситникова М.Ю., Лясникова Е.А., Юрченко А.В. и др. Результаты 3 лет работы Российского госпитального регистра хронической сердечной недостаточности (RUssian hoSpital Heart Failure Registry — RUS-HFR): взаимосвязь менеджмента и исходов у больных хронической сердечной недостаточностью. Кардиология. 2018;58(10S):9-19. doi:10.18087/cardio.2483.</mixed-citation><mixed-citation xml:lang="en">Sitnikova MYu, Lyasnikova EA, Yurchenko AV, et al. Results of 3 years work of the Russian hospital register of chronic heart failure (RUssian hoSpital Heart Failure Registry — RUS-HFR): relationship between management and outcomes in patients with chronic heart failure. Kardiologiia. 2018;58(10S):9-19. (In Russ.) doi:10.18087/cardio.2483.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Csige I, Ujvarosy D, Szabo Z, et al. The Impact of Obesity on the Cardiovascular System. J Diabetes Res. 2018;2018:3407306. doi:10.1155/2018/3407306.</mixed-citation><mixed-citation xml:lang="en">Csige I, Ujvarosy D, Szabo Z, et al. The Impact of Obesity on the Cardiovascular System. J Diabetes Res. 2018;2018:3407306. doi:10.1155/2018/3407306.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.</mixed-citation><mixed-citation xml:lang="en">Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев Д.А., Лясникова Е. А., Васильева А. А. и др. Молекулярный биомаркерный профиль хронической сердечной недостаточности с промежуточной и сохраненной фракцией выброса левого желудочка на фоне сахарного диабета 2 типа. Российский кардиологический журнал. 2020;25(10):3967. doi:10.15829/1560-4071-2020-3967.</mixed-citation><mixed-citation xml:lang="en">Lebedev DA, Lyasnikova EA, Vasilyeva AA, et al. Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes. Russ J Cardiol. 2020;25(10):3967. (In Russ.) doi:10.15829/1560-4071-2020-3967.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lebedev DA, Lyasnikova EA, Vasilyeva EY, et al. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis. J Diabetes Res. 2020;2020:6976153. doi:10.1155/2020/6976153.</mixed-citation><mixed-citation xml:lang="en">Lebedev DA, Lyasnikova EA, Vasilyeva EY, et al. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis. J Diabetes Res. 2020;2020:6976153. doi:10.1155/2020/6976153.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614-29. doi:10.1161/CIRCRESAHA118.312706.</mixed-citation><mixed-citation xml:lang="en">Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614-29. doi:10.1161/CIRCRESAHA118.312706.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Reinmann M, Meyer P. B-type natriuretic peptide and obesity in heart failure: a mysterious but important association in clinical practice. Cardiovasc Med. 2020;23:w02095. doi:10.4414/cvm.2020.02095.</mixed-citation><mixed-citation xml:lang="en">Reinmann M, Meyer P. B-type natriuretic peptide and obesity in heart failure: a mysterious but important association in clinical practice. Cardiovasc Med. 2020;23:w02095. doi:10.4414/cvm.2020.02095.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Clerico A, Zaninotto M, Passino C, et al. Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clin Chem Lab Med. 2018;56(7):1015-25. doi:10.1515/cclm-2017-0840.</mixed-citation><mixed-citation xml:lang="en">Clerico A, Zaninotto M, Passino C, et al. Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clin Chem Lab Med. 2018;56(7):1015-25. doi:10.1515/cclm-2017-0840.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Obokata M, Reddy YNV, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. doi:10.1161/CIRCULATIONAHA.116.026807.</mixed-citation><mixed-citation xml:lang="en">Obokata M, Reddy YNV, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. doi:10.1161/CIRCULATIONAHA.116.026807.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611-7. doi:10.1016/j.ijcard.2014.08.007.</mixed-citation><mixed-citation xml:lang="en">Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611-7. doi:10.1016/j.ijcard.2014.08.007.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Luchner A, Schunkert H. Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res. 2004;63(3):443-9. doi:10.1016/j.cardiores.2004.05.004.</mixed-citation><mixed-citation xml:lang="en">Luchner A, Schunkert H. Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res. 2004;63(3):443-9. doi:10.1016/j.cardiores.2004.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641.</mixed-citation><mixed-citation xml:lang="en">Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. doi:10.1002/ejhf.1494.</mixed-citation><mixed-citation xml:lang="en">Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. doi:10.1002/ejhf.1494.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. doi:10.1161/CIRCULATIONAHA.118.034646.</mixed-citation><mixed-citation xml:lang="en">Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. doi:10.1161/CIRCULATIONAHA.118.034646.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H, Jun DW, Cho YK, et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography. 2008;25(9):961-7. doi:10.1111/j.1540-8175.2008.00717.</mixed-citation><mixed-citation xml:lang="en">Kim H, Jun DW, Cho YK, et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography. 2008;25(9):961-7. doi:10.1111/j.1540-8175.2008.00717.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
